Diabetes obesity & metabolism, 1462-8902

Journal

Related Publications
  1. Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

    Ohkuma, T., Van Gaal, L., Shaw, W., Mahaffey, K. W., de Zeeuw, D., Matthews, D. R., Perkovic, V. & Neal, B., Apr-2020, In : Diabetes obesity & metabolism. 22, 4, p. 530-539 10 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis

    Scholtes, R. A., van Raalte, D. H., Correa-Rotter, R., Toto, R. D., Heerspink, H. J. L., Cain, V., Sjostrom, C. D., Sartipy, P. & Stefansson, B., Apr-2020, In : Diabetes obesity & metabolism. 22, 4, p. 549-556 8 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. A metabolomics based molecular pathway analysis for how the SGLT2-inhibitor dapagliflozin may slow kidney function decline in patients with diabetes

    Mulder, S., Hammarstedt, A., Nagaraj, S. B., Nair, V., Ju, W., Hedberg, J., Greasley, P. J., Eriksson, J. W., Oscarsson, J. & Heerspink, H. J. L., 1-Mar-2020, In : Diabetes obesity & metabolism. 11 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (59) »

ID: 4952827